Skip to main content

Mind Medicine Inc(MMED-NE)
Cboe CA

Today's Change
Real-Time Last Update

MindMed to Participate in March Investor Conferences

Business Wire - Tue Feb 28, 2023

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company's management team will participate in the following investor conferences:

  • Cowen 43rd Annual Healthcare Conference
  • Oppenheimer 33rd Annual Healthcare Conference
  • 35th Annual Roth Conference

Audio webcasts and replays of these presentations will be available on MindMed’s Investor Resources website for up to 90 days following each event.

About MindMed

MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders.

MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.

Provided Content: Content provided by Business Wire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe